NYMXF: CEO Dr. Paul Averback buys 102,844 shares

Rhea-AI Filing Summary

Nymox Pharmaceutical Corporation reported an insider share purchase. The company disclosed on Form 6-K that its CEO, Dr. Paul Averback, completed the purchase of 102,844 shares on October 20, 2025. The update records the transaction by the company’s chief executive and reflects an increase in his personal share ownership.

Insights

Securities disclosure analyst

Neutral administrative update: CEO bought 102,844 shares.

Nymox Pharmaceutical filed a Form 6-K noting that CEO Dr. Paul Averback purchased 102,844 shares on October 20, 2025. This is a straightforward insider transaction disclosure by a foreign private issuer.

The filing lists the transaction and the executive’s role without additional terms, pricing, or proceeds detail. As a result, investment impact cannot be assessed from this excerpt alone.

Subsequent company disclosures may provide broader context for ownership changes or governance, but this update stands as a factual record of the purchase.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of October, 2025

Commission File Number: 001-12033

Nymox Pharmaceutical Corporation

(Translation of registrant’s name into English)

Bay & Deveaux Streets, Nassau, The Bahamas

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

Nymox Pharmaceutical Corporation (the “Company”) reports that its CEO, Dr. Paul Averback, completed the purchase of 102,844 shares on October 20, 2025.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 22, 2025

	NYMOX PHARMACEUTICAL CORPORATION
	By:	/s/ Paul Averback
	Name:	Paul Averback
	Title:	President and Chief Executive Officer

3

FAQ

What did Nymox Pharmaceutical (NYMXF) disclose in this Form 6-K?

The company reported that CEO Dr. Paul Averback completed the purchase of 102,844 shares on October 20, 2025.

How many shares did Nymox’s CEO purchase and when?

Dr. Paul Averback purchased 102,844 shares on October 20, 2025.

Who made the share purchase reported by Nymox (NYMXF)?

The purchase was made by Dr. Paul Averback, Nymox’s President and Chief Executive Officer.

What filing type did Nymox use for this disclosure?

Nymox reported the transaction via a Form 6-K as a foreign private issuer.

Where is Nymox Pharmaceutical Corporation based?

The company’s principal executive office is at Bay & Deveaux Streets, Nassau, The Bahamas.